Dark

Check out our Level2View

TARS
Tarsus Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close

Sep 15, 2025 3:59:55 PM EDT

49.63USD+0.547%(+0.27)867,474

49.63Bid 49.68Ask 0.05Spread

Pre-market

Sep 15, 2025 8:48:30 AM EDT

49.75USD+0.790%(+0.39)100

After-hours

Sep 15, 2025 4:11:30 PM EDT

49.59USD-0.081%(-0.04)3,311

OverviewOptionsHistoricalExchangesShortsTrends

TARS Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

TARS Specific Mentions

As of Sep 15, 2025 11:45:23 PM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

10 days ago • u/pedronegreiros94 • r/stocks • biotech_pharma_small_caps_watchlist_2025 • Industry Discussion • B

|Name|Sector|Ticker|Key Catalyst|Mkt Cap(appox.)|
|:-|:-|:-|:-|:-|
||
|Halozyme|Biotech / Delivery|HALO|Growing royalties from ENHANZE; strong Q2 results|\~$8.6B|
|Tarsus|Pharma|TARS|XDEMVY approval and ramping sales|\~$2.4B|
|Delcath|Biotech|*PennyStock*|Early revenue growth from liver cancer treatment|\~$388M|
|Avadel|Pharma|AVDL|Growth of LUMRYZ for narcolepsy with market exclusivity|\~$1.5B|
|CorMedix|Biotech|CRMD|Launching DefenCath to reduce catheter infections|\~$1.0B|
|Atai Life Sciences|Pharma|ATAI|Early promising 5-MeO-DMT depression trials|\~$960M|
|Eton Pharma|Pharma|ETON|FDA approval for epilepsy drug (stock +16%)|\~$470M|
|Madrigal Pharma|Biotech|MDGL|Strong market cap growth (\~+72% 1-year)|\~$9.6B|

10 days ago • u/pedronegreiros94 • r/stocks • biotech_pharma_small_caps_watchlist_2025 • Industry Discussion • B

|Name|Sector|Ticker|Key Catalyst|Mkt Cap(appox.)|
|:-|:-|:-|:-|:-|
||
|Halozyme|Biotech / Delivery|HALO|Growing royalties from ENHANZE; strong Q2 results|\~$8.6B|
|Tarsus|Pharma|TARS|XDEMVY approval and ramping sales|\~$2.4B|
|Delcath|Biotech|*PennyStock*|Early revenue growth from liver cancer treatment|\~$388M|
|Avadel|Pharma|AVDL|Growth of LUMRYZ for narcolepsy with market exclusivity|\~$1.5B|
|CorMedix|Biotech|CRMD|Launching DefenCath to reduce catheter infections|\~$1.0B|
|Atai Life Sciences|Pharma|ATAI|Early promising 5-MeO-DMT depression trials|\~$960M|
|Eton Pharma|Pharma|ETON|FDA approval for epilepsy drug (stock +16%)|\~$470M|
|Madrigal Pharma|Biotech|MDGL|Strong market cap growth (\~+72% 1-year)|\~$9.6B|

Share